Announcing my #ASHNewsDaily Golden Globule award picks for @ash.hematology.org #ASH25! I gave my awards to the best (shocker) patient-reported outcomes abstracts, including quality of life studies from trials and in real-world practice. #MajorPROsASH ashpublications.org/ashnewsdaily...
Happy #ASH25 day!
Check out all of this year's #MajorPROsASH, the top 20 best patient-reported outcomes & quality of life abstracts from this year's @ash.hematology.org meeting.
Check out the hashtag for details on all the abstracts: bsky.app/hashtag/Majo...
1 – #MajorPROsASH – 709 Karmali
Liso-cel in R/R MZL: early deterioration in multiple QoL domains by D15. However, by 3 months after liso-cel, QoL rebounds above pre-CAR baseline & sustained until 18 months after liso-cel! Now FDA approved w/ meaningful QoL benefits. #lymsm #ASH25 @ash.hematology.org
2 – #MajorPROsASH – 5509 Budde
Mosun-pola w/ sig prolonged TTD of phys fxn, #lymsm related sx, and neuropathy vs R-GemOx. Fatigue improved with mosun-pola (no change R-GemOx). Pain improved faster w/ mosun-pola. QoL & PFS improvements in palliative setting. #ASH25 @ash.hematology.org
3 – #MajorPROsASH – 5370 Linton
EPCORE FL-1 PROs: Functional QOL + side effect burden initially worsens w/ epco+R2, recovers by C5D1. Otherwise no clinically meaningful worsening in QoL by EOT w/ epco+R2 or R2. Can counsel pts about dynamic QoL changes over time. #ASH25 #lymsm @ash.hematology.org
4 – #MajorPROsASH – 5362 Frustaci
Prospective frailty & PROs WM: Nearly all pts w/ at least 1 impaired geri domain. Functional/psychological status & lack of social support significantly associated with inferior QoL. PRO + geri assessment can stratify frailty in WM. #ASH25 #lymsm @ash.hematology.org
5 – #MajorPROsASH – 522 Lapen
Novel PRO tool for RT in CTCL (Skindex-16 + PRO-CTCAE + EORTC QLQ-C30). Improved QoL 1 month post RT & sustained thru 6 months. TSEBT w/ better QoL improvements vs focal RT. Severe fatigue during RT improved by 1 month. RT improves QoL! #lymsm #ASH25 @ash.hematology.org
6 – #MajorPROsASH – 2738 Davison
S1826: N-AVD w/ worse fatigue at EOT and less neuropathy at 1 yr in all ages. BV-AVD w/ worse neuropathy only in adults. Global QoL better for adults on N-AVD, but no diff in adolescents. PROs across whole age spectrum can be collected! #lymsm @ash.hematology.org
7 – #MajorPROsASH – 138 Efficace
Frailty + PRO model RRMM: patient-reported physical functioning (PF) is associated with OS in multivariable model, including IMWG frailty index. Adding PF to frailty model improved fit vs frail. Future for PROs in tx decision-making! #mmsm @ash.hematology.org
8 – #MajorPROsASH – 2263 Mai
Isa-RVd v Rvd in NDMM: Adding isa = improved fatigue, pain, and future perspectives. Both study arms: better phys/emotional functioning. Similar to D-RVd data; quads can improve QoL in #mmsm. #ASH25 @ash.hematology.org
9 – #MajorPROsASH – 4029 @sagarlonialmd.bsky.social
DREAMM-7 BVd v DVd: 1/3 new ocular AEs w/ belamaf. However, global QoL & functioning were maintained (& comparable to DVd) despite ocular AEs. BVd also w/ longer TTD phys fxn & #mmsm related sx. Great PRO data to give PFS context. #ASH25
10 – #MajorPROsASH – 406 Berenson
Remote symptom monitoring (RSM) by SMS #mmsm: >87% PRO completion rates, <3 minutes per survey. 44% of symptom alerts were acted upon. Scalable real-time RSM is holy grail in real-world PROs to improve tx tolerability (& survival). #ASH25 @ash.hematology.org
11 – #MajorPROsASH – 540 Hermans
Mim8 (F8 BsAb mimetic) ppx #hemophilia A: clinically-meaningful improvements in PRO-assessed treatment burden, physical fxn & joint pain at 1 year. PROs similar between qweek & qmonth dosing. >88% preferred Mim8 over previous on-demand tx. #ASH25 @ash.hematology.org
12 – #MajorPROsASH – 949 @AustinKulasekar
Danicopan add-on tx in PNH: significant improvements in Hgb, transfusion independence, and PRO-assessed fatigue. Younger & older pts had better fatigue w/ danicopan (no fatigue changes in placebo arm). Can improve QoL w/ add-on tx! #ASH25 @ash.hematology.org
13 – #MajorPROsASH – 614 Anishchenko
EPO + hydroxyurea in #sicklecell disease: Hgb gain of ~3 g/dL plus improvements in pain, physical/role functioning, fatigue & mental health. Pilot study in US & Nigeria with provocative finding that EPO may reduce pain in #SCD. #ASH25 @ash.hematology.org
14 – #MajorPROsASH – 4278 Guilcher
Children & AYA pts w/ #sicklecell disease receiving alloSCT: substantial QoL improvements and low decisional regret up to 3 yrs after allo. Study supports shared decision-making in #SCD that includes long-term⬆️QoL outcomes. #bmtsm #ASH25 @ash.hematology.org
15 – #MajorPROsASH – 4682 Kelley
Single-dose IV ferric derisomaltose in pregnancy: Hgb improvement at 6 wks post-partum, as well as significant improvements in fatigue & depression PROs. Critically important trial in pregnancy that supports QoL benefits of IV iron. #ASH25 #obgyn @ash.hematology.org
16 – #MajorPROsASH – 6245 Carpenedo
Efgartigimod in ITP:⬆️physical & mental functioning and⬇️fatigue vs placebo. Placebo pts who crossed over to efgartigimod also had PRO improvements. Sustained QoL improvements with long-term dosing. ITP is a very symptomatic disease! #ASH25 @ash.hematology.org
17 – #MajorPROsASH – 2117 Schwaner
Fixed-duration VO 1L CLL: clinically sig⬆️in global QoL that improves after tx completion, regardless of age or TP53/IGHV status. Fatigue & CLL sx burden also improve. Great RW data for pt counseling with common 1L #cllsm regimen. #lymsm #ASH25 @ash.hematology.org
18 – #MajorPROsASH – 2685 Efficace
Patients with VEXAS: significantly worse physical/role/social functioning, fatigue, and pain vs matched MDS controls. Treatment did not improve QoL. Myalgias, arthralgias, skin PROs unique to VEXAS. Important PRO work in a #raredisease. #ASH25 @ash.hematology.org
19 – #MajorPROsASH – 2749 Rangel
Sexual health & QoL in #leusm survivors: Significantly worse sexual function, pain/discomfort, & communication w/ partners vs matched healthy controls, despite similar self-esteem. Major unmet survivorship domain & need for multiD approach. #ASH25 @ash.hematology.org
20 – #MajorPROsASH – 559 Bashir
New CLIPI prognostic score in adv-stage CTCL correlates with Skindex-29 skin-related QoL. Higher CLIPI strata with significantly worse symptom & functioning scores, supporting CLIPI as both a prognostic and QoL-relevant tool in CTCL. #lymsm #ASH25 @ash.hematology.org
Happy #ASH25 week!🎉
This week, I'll be posting this year’s #MajorPROsASH, my curated list of the top 20 patient-reported outcomes (PRO) abstracts from the @ash.hematology.org Annual Meeting.
How patients feel & function belongs next to survival curves! Follow the hashtag: bsky.app/search?q=%23...
Get stoked for this year’s #MajorPROsASH!
I’m currently reviewing all the patient-reported outcomes (PRO) abstracts @ash.hematology.org to curate the top 20 PRO & quality of life abstracts from #ASH25.
Thread dropping next week! 🧵 #mmsm #leusm #lymsm
Honorable mention #MajorPROsASH: PROMIS PROs 106 pts w/ MCL after ASCT @DiMengyang
- LTFU (median 9 yrs): ~3/4 with good or better QOL domains
- however, 16-18% w/ worse physical & cognitive fxn (compared to general pop)
- worse phys fxn = less likely to be working
1/ #ASH24
Poster #ASH24: better improvements in pain & fatigue at D+90 post #mmsm CAR in underrepresented minorities. However, also notice 29% of minorities with worsening fatigue; subgroup analysis to better understand predictors of better vs worse fatigue. #MajorPROsASH
Poster #ASH24: clinically meaningful improvements in pain, fear, emotional wellbeing at 3 mos post-axicel. Significant worsening in fatigue at 1-mo timepoint; seen in other studies (like ours: www.sciencedirect.com/science/arti...) and improves after 3 months. #MajorPROsASH #lymsm
Masterful #ASH24 oral on PROs in HOVON141 (#ASHKudos to @ASH_hematology for including PROs in primary trial sessions!) 🧵
- 224 pts, 83% PRO completion 2 yrs, down to 52% at 3 yrs
- improvement in global QOL above MID which is sustained (only 15% had worsening)
1/ #MajorPROsASH
Poster #ASH24: less deterioration of phys fx in glofi arm, also less pain (including sustained improvement in pain) & lymphoma-related symptoms in glofi arm. #MajorPROsASH #lymsm
Honorable mention #MajorPROsASH: real-world PROs w/ 1L dara
Like the trials, significant & sustained improvements in phys health (& anxiety/depression) with 1L dara-containing regimens. Further supports trial data (especially MAIA) showing improvements in QOL & pain. #ASH24 #mmsm
